Ascendia

  MARKET NEWS

NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
AnaMar Announces Positive Phase 1 Data for its Phase 2 Ready Compound for Treating Fibrosis
Ocean Biomedical, Inc. Announces Patent Award for Novel Cancer Immunotherapy Treatment Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma & Lung Cancer
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration & Diabetic Macular Edema
Oculis Announces Positive Top Line Results From DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema With OCS-01 Eye Drops

  FEATURED EDITORIAL

  COMPANY PROFILE

One World DMG is a leading designer and manufacturer of injection trainers and patient onboarding materials for the pharmaceutical and biopharmaceutical industries. For 25 years we’ve pioneered the development of injection training tools that provide the most authentic injection experience possible. Our trainers have proven effective both in the medical setting and in patients’ homes, where comfort with self-injection is crucial to adherence and better health outcomes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Valo Therapeutics Announces First Patient Dosed With PeptiCRAd-1 - Innovative Immuno-Oncology

Valo Therapeutics Announces First Patient Dosed With PeptiCRAd-1 - Innovative Immuno-Oncology

Valo Therapeutics Oy (ValoTx) recently announced the first patient has been treated in its Phase 1 trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor….

Roquette Announces Strategic Investment & Innovation Agreement With Beren Therapeutics P.B.C.

Roquette Announces Strategic Investment & Innovation Agreement With Beren Therapeutics P.B.C.

Roquette recently announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal….

Circulating Tumor Cells Isolated With Unique TellDx Technology May Help Predict Response to Therapy in Patients With Progressive Metastatic Breast Cancer

Circulating Tumor Cells Isolated With Unique TellDx Technology May Help Predict Response to Therapy in Patients With Progressive Metastatic Breast Cancer

TellBio, Inc. recently announced publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of….

Cell & Gene Therapy CDMO Targets North American Growth With Major US Acquisition

Cell & Gene Therapy CDMO Targets North American Growth With Major US Acquisition

uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell & gene therapy (CGT) CDMO has an….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

  WHITEPAPERS & WEBINARS

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 31 – Controlled Release
June 7 – Prefilled Syringes